Target intelligence / Profile preview

Guanylate kinase 1 (GUK1)

Target
GUK1
Molecular classification
Enzyme
01

Overview

Guanylate kinase 1 is an essential cytoplasmic enzyme that catalyzes the phosphorylation of guanosine monophosphate (GMP) to guanosine diphosphate (GDP) using ATP. It is the principal enzyme responsible for maintaining the balance of nucleotide pools required for DNA and RNA synthesis, cell proliferation, and cell survival. Guanylate kinase 1 also plays a critical role in the metabolic activation of several nucleoside analog prodrugs used in the treatment of cancer and viral infections, such as 6-thioguanine, 6-mercaptopurine, ganciclovir, and acyclovir. Functional loss or inhibition of this enzyme disrupts nucleotide homeostasis and can impair cancer cell viability. Structure-function studies show that human guanylate kinase consists of three domains—LID, GMP-binding, and CORE domains. Its pharmacological relevance makes it an emerging target for anticancer and antiviral therapy.

Other names
GMKhGMPK
02

Mechanism of action

Prodrug activation: catalyzes phosphorylation of nucleoside analogs for antineoplastic and antiviral effect

03

Biological functions

Nucleotide metabolismPurine biosynthesis and salvageCell proliferationDNA/RNA synthesisActivation of nucleoside analog prodrugs
04

Disease associations

CancerInfection (as relevant to antiviral drug activation)Other (related to nucleotide pool homeostasis and cell survival)
05

Safety considerations

Inhibition may affect normal DNA/RNA synthesis, potentially leading to off-target effects on healthy proliferating cells (e.g., bone marrow)Genetic variants can influence enzymatic activity, affecting drug responsiveness or adverse reactions
06

Interacting drugs

6-thioguanine

4 more in the full profile.

07

Biomarkers

Changes in GUK1 expression or activity can influence response to nucleoside analog drugs and may impact cancer cell proliferation; specific biomarkers are not routinely established but enzyme activity could serve as a biomarker for therapy efficacy

Beyond the preview

Go deeper on Guanylate kinase 1 (GUK1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guanylate kinase 1 (GUK1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call